JP2022516974A5 - - Google Patents
Info
- Publication number
- JP2022516974A5 JP2022516974A5 JP2021539935A JP2021539935A JP2022516974A5 JP 2022516974 A5 JP2022516974 A5 JP 2022516974A5 JP 2021539935 A JP2021539935 A JP 2021539935A JP 2021539935 A JP2021539935 A JP 2021539935A JP 2022516974 A5 JP2022516974 A5 JP 2022516974A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- pharmaceutical composition
- composition according
- active agent
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024059887A JP2024081769A (ja) | 2019-01-09 | 2024-04-03 | 多発性骨髄腫の治療における抗増殖化合物及び第２の活性薬剤とそれらの併用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962790326P | 2019-01-09 | 2019-01-09 | |
| US62/790,326 | 2019-01-09 | ||
| PCT/US2020/012647 WO2020146440A1 (en) | 2019-01-09 | 2020-01-08 | Antiproliferative compounds and second active agents for use in treating multiple myeloma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024059887A Division JP2024081769A (ja) | 2019-01-09 | 2024-04-03 | 多発性骨髄腫の治療における抗増殖化合物及び第２の活性薬剤とそれらの併用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022516974A JP2022516974A (ja) | 2022-03-03 |
| JP2022516974A5 true JP2022516974A5 (https=) | 2023-01-24 |
| JP7467479B2 JP7467479B2 (ja) | 2024-04-15 |
Family
ID=69500830
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539935A Active JP7467479B2 (ja) | 2019-01-09 | 2020-01-08 | 多発性骨髄腫の治療における抗増殖化合物及び第２の活性薬剤とそれらの併用方法 |
| JP2024059887A Pending JP2024081769A (ja) | 2019-01-09 | 2024-04-03 | 多発性骨髄腫の治療における抗増殖化合物及び第２の活性薬剤とそれらの併用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024059887A Pending JP2024081769A (ja) | 2019-01-09 | 2024-04-03 | 多発性骨髄腫の治療における抗増殖化合物及び第２の活性薬剤とそれらの併用方法 |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US11660297B2 (https=) |
| EP (2) | EP3908281B9 (https=) |
| JP (2) | JP7467479B2 (https=) |
| KR (1) | KR20210126011A (https=) |
| CN (3) | CN114404596A (https=) |
| AU (1) | AU2020205643C1 (https=) |
| CA (1) | CA3125753A1 (https=) |
| DK (1) | DK3908281T3 (https=) |
| EA (1) | EA202191903A1 (https=) |
| ES (1) | ES2995189T3 (https=) |
| FI (1) | FI3908281T3 (https=) |
| HR (1) | HRP20241309T1 (https=) |
| HU (1) | HUE068895T2 (https=) |
| IL (1) | IL284671B2 (https=) |
| LT (1) | LT3908281T (https=) |
| MX (2) | MX2021008294A (https=) |
| PL (1) | PL3908281T3 (https=) |
| PT (1) | PT3908281T (https=) |
| RS (1) | RS66066B1 (https=) |
| SG (1) | SG11202107413YA (https=) |
| SI (1) | SI3908281T1 (https=) |
| SM (1) | SMT202400388T1 (https=) |
| WO (1) | WO2020146440A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021521170A (ja) * | 2018-04-13 | 2021-08-26 | スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド | 骨髄増殖性新生物およびがんに関連する線維症の処置のためのｐｉｍキナーゼ阻害剤 |
| WO2020146441A1 (en) * | 2019-01-09 | 2020-07-16 | Celgene Corporation | Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same |
| FI3908281T3 (fi) * | 2019-01-09 | 2024-10-01 | Celgene Corp | Antiproliferatiivisia yhdisteitä ja toisia aktiivisia aineita käytettäväksi multippelin myelooman hoidossa |
| AU2022207648A1 (en) | 2021-01-13 | 2023-07-27 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| MX2023009858A (es) * | 2021-02-25 | 2023-09-12 | Impact Biomedicines Inc | Uso de inhibidores de proteina de bromodominio y motivo extraterminal (bet) solo o en combinacion con fedratinib o ruxolitinib como tratamiento para una malignidad hematologica tal como la mielofibrosis. |
| KR20240013793A (ko) | 2021-05-27 | 2024-01-30 | 셀진 코포레이션 | 조합 요법을 사용하는 다발성 골수종의 치료 방법 |
| US20230142647A1 (en) * | 2021-07-12 | 2023-05-11 | Quteba Ebrahem | Method of treating cancer or a blood disorder |
| CN116496246A (zh) * | 2022-01-18 | 2023-07-28 | 中国药科大学 | 异吲哚啉类化合物、制备方法、药物组合物和应用 |
| CN117045800A (zh) * | 2022-05-06 | 2023-11-14 | 上海科技大学 | mTOR抑制剂增强靶向蛋白降解药物功效的应用 |
| CN119015299A (zh) * | 2024-08-21 | 2024-11-26 | 中国医学科学院肿瘤医院 | 西奈芬净在治疗癌症中的应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5948893A (en) | 1996-01-17 | 1999-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody |
| US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| US8628927B2 (en) | 2008-11-07 | 2014-01-14 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ | Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用 |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| WO2011082400A2 (en) | 2010-01-04 | 2011-07-07 | President And Fellows Of Harvard College | Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
| PL3202460T3 (pl) | 2010-02-11 | 2019-12-31 | Celgene Corporation | Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania |
| WO2011159877A2 (en) | 2010-06-18 | 2011-12-22 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| AU2015300966A1 (en) | 2014-08-08 | 2017-02-16 | Janssen Pharmaceutica Nv | Bruton's tyrosine kinase inhibitor combinations and uses thereof |
| AU2015301746A1 (en) | 2014-08-13 | 2017-02-16 | Celgene Corporation | Combination therapy for treating cancer |
| KR20200020899A (ko) * | 2017-06-30 | 2020-02-26 | 셀진 코포레이션 | 2-(4-클로로페닐)-n-((2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린-5-일)메틸)-2,2-디플루오로아세트아미드의 조성물 및 사용 방법 |
| EP4467143B1 (en) * | 2017-07-10 | 2026-03-11 | Celgene Corporation | Method for preparing 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile |
| PL3796912T3 (pl) * | 2018-05-23 | 2023-09-11 | Celgene Corporation | Związki przeciwproliferacyjne i przeciwciało bispecyficzne przeciwko bcma i cd3 do zastosowania kombinowanego |
| FI3908281T3 (fi) * | 2019-01-09 | 2024-10-01 | Celgene Corp | Antiproliferatiivisia yhdisteitä ja toisia aktiivisia aineita käytettäväksi multippelin myelooman hoidossa |
-
2020
- 2020-01-08 FI FIEP20704117.9T patent/FI3908281T3/fi active
- 2020-01-08 CN CN202210009586.2A patent/CN114404596A/zh active Pending
- 2020-01-08 CN CN202410171019.6A patent/CN118178417A/zh active Pending
- 2020-01-08 DK DK20704117.9T patent/DK3908281T3/da active
- 2020-01-08 PT PT207041179T patent/PT3908281T/pt unknown
- 2020-01-08 WO PCT/US2020/012647 patent/WO2020146440A1/en not_active Ceased
- 2020-01-08 IL IL284671A patent/IL284671B2/en unknown
- 2020-01-08 EP EP20704117.9A patent/EP3908281B9/en active Active
- 2020-01-08 SG SG11202107413YA patent/SG11202107413YA/en unknown
- 2020-01-08 MX MX2021008294A patent/MX2021008294A/es unknown
- 2020-01-08 LT LTEPPCT/US2020/012647T patent/LT3908281T/lt unknown
- 2020-01-08 SI SI202130207T patent/SI3908281T1/sl unknown
- 2020-01-08 CN CN202080018980.1A patent/CN113543786A/zh active Pending
- 2020-01-08 HU HUE20704117A patent/HUE068895T2/hu unknown
- 2020-01-08 ES ES20704117T patent/ES2995189T3/es active Active
- 2020-01-08 JP JP2021539935A patent/JP7467479B2/ja active Active
- 2020-01-08 EA EA202191903A patent/EA202191903A1/ru unknown
- 2020-01-08 SM SM20240388T patent/SMT202400388T1/it unknown
- 2020-01-08 CA CA3125753A patent/CA3125753A1/en active Pending
- 2020-01-08 KR KR1020217025057A patent/KR20210126011A/ko not_active Ceased
- 2020-01-08 AU AU2020205643A patent/AU2020205643C1/en active Active
- 2020-01-08 EP EP24191518.0A patent/EP4461370A3/en active Pending
- 2020-01-08 US US16/737,710 patent/US11660297B2/en active Active
- 2020-01-08 HR HRP20241309TT patent/HRP20241309T1/hr unknown
- 2020-01-08 RS RS20241127A patent/RS66066B1/sr unknown
- 2020-01-08 PL PL20704117.9T patent/PL3908281T3/pl unknown
-
2021
- 2021-07-08 MX MX2024008439A patent/MX2024008439A/es unknown
-
2023
- 2023-04-25 US US18/139,151 patent/US12186311B2/en active Active
-
2024
- 2024-04-03 JP JP2024059887A patent/JP2024081769A/ja active Pending
- 2024-11-21 US US18/955,085 patent/US20250082629A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022516974A5 (https=) | ||
| US20230190760A1 (en) | Advantageous therapies for disorders mediated by ikaros or aiolos | |
| ES2521672T3 (es) | Formulaciones farmacéuticas para el tratamiento del cáncer | |
| JP2022546471A5 (https=) | ||
| FI3908281T3 (fi) | Antiproliferatiivisia yhdisteitä ja toisia aktiivisia aineita käytettäväksi multippelin myelooman hoidossa | |
| JP2023515817A (ja) | ダブラフェニブ、ｅｒｋ阻害剤及びｓｈｐ２阻害剤を含む三重の医薬品の組合せ | |
| KR20180113976A (ko) | 암을 치료하기 위한 테트라사이클릭 퀴놀론 유사체의 병행 요법 | |
| BR102019002873A2 (pt) | inibidores de pd-1/pd-l1 | |
| US20150005262A1 (en) | Hypoxia activated prodrugs and mtor inhibitors for treating cancer | |
| JP2022552880A (ja) | 置換４－アミノイソインドリン－１，３－ジオン化合物および組合せ使用のための第２の活性剤 | |
| JP2018530578A (ja) | 組み合せ抗細菌組成物および短期抗細菌レジメン | |
| CN118201615A (zh) | 喹唑啉酮化合物用于治疗癌症的新用途 | |
| JP2022535893A5 (https=) | ||
| AU2018234903B2 (en) | Combination therapies for the treatment of breast cancer | |
| KR101307650B1 (ko) | 구역에 대한 경피 방법 및 패치 | |
| JP2018525411A (ja) | 多発性骨髄腫を治療するためのｂｔｋ阻害剤の組み合わせ | |
| US20170135990A1 (en) | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection | |
| PL193797B1 (pl) | Zastosowanie reboksetyny albo jej farmaceutyczniedopuszczalnych soli | |
| JP2019513706A (ja) | オナプリストン代謝物質組成物及び方法 | |
| US9951041B2 (en) | Crystalline C21H22Cl2N4O2 malonate | |
| EP0528749B1 (en) | Indole derivatives and their use | |
| JP2018515507A5 (https=) | ||
| CN106061505A (zh) | 用于治疗癌症的含pi3k抑制剂的药物组合 | |
| BR112020016389A2 (pt) | Uso de 5-fluor-4-(4-fluor-2-metoxifenil)-n-{4-[(s-metilsulfonimidoil)metil]piridin-2-il}piridin-2-amina para tratamento de linfoma difuso de células b grandes | |
| WO2018213770A1 (en) | Therapeutic methods |